← Every company
Biogen Inc Patents
What Biogen Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
BIIB on carbonthat →Filings on file
51
Granted
0
Still pending
51
Filed under
4 names
51 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| FLUID CATHETER DEVICE FOR RECORDING BRAIN STATEA61B 5/0538, A61M 27/006, A61B 5/293, A61B 5/6852, A61B 5/6864, A61B 5/6868, A61M 25/0026, A61M 39/0247, A61M2039/0273, A61M2039/0276Filed as Biogen MA Inc.2026-05-14Daniel J. Abrams | pending |
| MONOVALENT ANTIBODIES AND USES THEREOFFiled as BIOGEN MA INC.2026-03-06R. BLAKE PEPINSKY | pending |
| 2'-OH DEPROTECTION PROCESS OF RIBONUCLEIC ACIDFiled as BIOGEN MA INC.2026-02-27XUAN ZHOU | pending |
| ANTI-BETA AMYLOID/ANTI-TRANSFERRIN RECEPTOR BISPECIFIC ANTIBODIES AND USES THEREOFFiled as BIOGEN MA INC.2026-02-05JOSEPH WALTER ARNDT | pending |
| IMPLANTABLE MEDICAL DEVICE FOR USE WITH OR HAVING RECORDING ELECTRODEA61M 27/006, A61N 1/0539, A61B 5/293, A61B 5/262, A61B 5/37, A61B 5/6848, A61B 5/6852, A61B 5/6864, A61B 5/6868, A61B2562/0209Filed as Biogen MA Inc.2026-02-04Daniel J. Abrams | pending |
| ALLYLOXYCARBONYL REAGENTS, OLIGONUCLEOTIDES, AND PREPARATION THEREOFFiled as BIOGEN MA INC.2026-01-09THOMAS CHARLES PICKEL II | pending |
| GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOFC07D 471/04, A61P 25/28, A61P 35/02, A61P 3/10, A61P 25/18, A61P 25/00, A61P 25/16, A61P 35/00, A61K 31/4375, A61K 31/438, A61K 31/444, A61K 31/4709, A61K 31/501, A61K 31/506, A61K 31/5377, C07D 471/10, C07D 471/14, C07D 471/20, C07D 491/20Filed as Biogen MA Inc.2025-12-12Florence Fevrier Wagner | pending |
| EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOFA61K 31/403, C07D 405/12, A61P 37/00, A61P 25/28, A61P 25/00, A61K 31/407, A61K 31/4155, A61K 31/4439, A61K 31/454, A61K 31/5377, C07D 401/04, C07D 405/14, C07D 413/04, C07D 487/04, C07D 519/00Filed as BIOGEN MA INC.2025-12-05Felix Gonzalez Lopez de Turiso | pending |
| COMPOSITIONS AND METHODS FOR ADENO-ASSOCIATED VIRUS PRODUCTIONFiled as BIOGEN MA INC.2025-11-21NARENDRA MAHESHRI | pending |
| BTK INHIBITOR FOR TREATING MULTIPLE SCLEROSISA61K 31/55, A61P 37/00, A61P 25/28, A61K 9/0056Filed as BIOGEN MA INC.2025-11-03Michael SOLIMAN | pending |
| ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOFA61K 38/1793, C07K 14/7151, A61P 17/06, A61P 19/02, A61K 9/0019, A61K 38/00, A61K 39/3955, A61K2039/505, A61K2039/545, C07K 14/525, C07K 16/241, C07K2317/21, C07K2319/30, C07K2319/70Filed as BIOGEN MA INC.2025-10-21Jeehoon GHIL | pending |
| METHODS FOR PREPARING OLIGONUCLEOTIDE CONJUGATESFiled as BIOGEN MA INC.2025-10-17JONAS P. IMMEL-BROWN | pending |
| IMMUNOSUPPRESSIVE REGIMENS AND METHODS THEREOFA61P 37/06, A61K 31/573, A61P 25/00, A61K 31/343, A61K 31/436, A61K 31/519, A61K 31/7105, A61K 48/0033, A61K 48/005, A61K 48/0075, C12N 15/86, C12N2750/14143, A61K2300/00Filed as Biogen MA Inc.2025-10-10Dale Morris | pending |
| 1 H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASESC07D 471/04, A61P 27/02, A61P 7/02, A61P 17/06, A61P 21/00, A61P 37/02, A61P 9/10, A61P 25/28, A61P 1/16, A61P 9/00, A61P 17/14, A61P 31/12, A61P 3/04, A61P 15/02, A61P 17/00, A61P 19/02, A61P 25/04, A61P 3/10, A61P 31/04, A61P 9/04, A61P 11/00, A61P 29/00, A61P 1/04, A61P 19/10, A61P 35/00, A61K 31/428, A61K 31/4355, A61K 31/437, A61K 31/444, A61K 31/5025, C07D 417/14, C07D 487/04, C07D 491/04, C07D 491/048, C07D 495/04, C07D 498/04, C07D 513/04Filed as BIOGEN MA INC.2025-10-03Nathan Edward Genung | pending |
| ADDITIVES FOR VIRAL VECTOR PRODUCTIONFiled as BIOGEN MA INC.2025-09-11MARIA CHUNG ME CHOI-ALI | pending |
| PACKAGING PLASMIDS FOR AAV PRODUCTIONC12N 15/63, C12N 15/8645, A61K 35/761, C07K 14/075, C12N 7/025, C12N 15/85, C12N 15/86, C12N2710/10022, C12N2710/10044, C12N2750/14143, C12N2750/14152, C12N2800/10, C12N2830/00, C12N2830/34Filed as Biogen MA Inc.2025-09-09Terrence Michael Dobrowsky | pending |
| ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOFA61P 25/00, C07K 16/2881, A61K 47/6913, A61K 47/6929, A61K 47/6807, A61K 47/6815, A61K 47/6901, A61K 47/6803, A61K 47/6849, A61P 25/28, A61K2039/505, C07K 16/18, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/52, C07K2317/55, C07K2317/565, C07K2317/622, C07K2317/92, C07K2319/42, C12Y 302/01045Filed as Biogen MA Inc.2025-09-05Thomas Owen Cameron | pending |
| AAV PARTICLES COMPRISING RGD-CONTAINING PEPTIDES FOR DELIVERING DYSTROPHIN PAYLOADSFiled as BIOGEN MA INC.2025-08-20ADELAIDA PALLA CACHORRO | pending |
| METHOD OF ASSESSING RISK OF PMLG01N 33/6854, C07K 16/2842, C07K2317/24, C12N 7/00, C12N2710/22011, C12Q 1/70, G01N 33/56983, G01N2333/025, G01N2469/20, G01N2800/24, G01N2800/28, G01N2800/50Filed as BIOGEN MA INC2025-08-19Gary Lewis BLOOMGREN | pending |
| RGD-CONTAINING PEPTIDES FOR DELIVERING PAYLOADSFiled as Biogen MA Inc.2025-08-14Adelaida Palla Cachorro | pending |
| METHODS FOR TREATING ALZHEIMER'S DISEASEFiled as BIOGEN MA INC.2025-07-25GAUTAM BAHETI | pending |
| IMPLANTABLE INTRAVENTRICULAR SAMPLING AND INFUSION ACCESS DEVICEA61M 5/14276, A61B 10/0045, A61B2010/0077, A61M 5/16831, A61M 25/003, A61M 39/02, A61M 39/0208, A61M2005/1406, A61M2025/0031, A61M2210/0693Filed as Biogen MA Inc.2025-07-24Daniel J. Abrams | pending |
| Methods for Treating Alzheimer's DiseaseC07K 16/18, A61P 25/28, A61K 39/3955, A61K2039/505, A61K2039/545, C07K2317/51, C07K2317/515, C07K2317/52Filed as Biogen International Neuroscience GmbH2025-07-10Brendon Phillip Boot | pending |
| Method for Treating Alzheimer's DiseaseA61P 25/28, A61K 39/3955, C07K 16/18, A61K2039/505, A61K2039/54, A61K2039/545, C07K 16/28, C07K2317/21Filed as Biogen International Neuroscience GmbH2025-06-16James L. Ferrero | pending |
| CYCLOOCTENE COMPOSITIONS AND USES THEREOFC07D 487/08, C07C2601/18, A61K 51/04, A61K 51/0446, A61K 51/0455, A61K 51/0459, A61K 51/0468, C07B 59/001, C07B 59/002, C07B2200/05, C07C 235/48, C07D 209/46, C07D 213/64, C07D 213/74, C07D 213/82, C07D 295/205, C12N 15/113, C12N2310/11, C12N2320/31, C12N2320/32Filed as BIOGEN MA INC.2025-06-13Thomas Charles Pickel, II | pending |
| REAGENTS AND PROCESSES FOR PREPARING OLIGONUCLEOTIDESFiled as BIOGEN MA INC.2025-05-08XUAN ZHOU | pending |
| METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMENA61K 38/21, A61K 9/0019, A61K 38/215, A61K2300/00, C07K 14/565Filed as Biogen MA Inc.2025-05-05Aaron DEYKIN | pending |
| COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSAC12N 15/86, C12N 15/8645, A61P 27/02, A61K 9/0019, A61K 9/0048, A61K 31/56, A61K 31/711, A61K 38/00, A61K 48/005, C12N 15/11, C12N2750/14143, C12N2830/15, C12N2830/34, C12N2830/48, C12N2830/50Filed as Biogen MA Inc.2025-04-18Kip Michael Connor | pending |
| GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOFC07D 471/20, A61K 31/437, A61K 31/4375, A61K 31/438, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/4745, A61K 31/4747, A61K 31/496, A61K 31/497, A61K 31/4985, A61K 31/501, A61K 31/5025, A61K 31/506, A61K 31/519, A61K 31/5365, A61K 31/5377, A61K 31/538, A61K 31/5383, A61K 31/55, C07D 471/04, C07D 471/10, C07D 471/14, C07D 491/20, C07D 491/22, C07D 495/20, C07D 495/22, C07D 519/00Filed as Biogen MA Inc.2025-04-10Florence Fevrier Wagner | pending |
| METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHYA61K 31/712, C12N 15/113, C12N 15/1136, A61P 21/00, A61P 25/28, A61K 9/0021, A61K 31/7088, A61K 31/7125, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/346, C12N2310/3525, C12N2320/33, C12N2320/34, C12N2320/35, G01N 33/68, G01N 33/6896Filed as Biogen MA Inc.2025-04-07Kenneth Swope Loveday | pending |
| AAV CAPSIDS COMPRISING ANTI-TRANSFERRIN ANTIBODY DOMAINSFiled as BIOGEN MA INC.2025-03-27JOSEPH WALTER ARNDT | pending |
| ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOFFiled as BIOGEN MA INC.2025-03-27MARK CHRISTOPHER JULIAN | pending |
| AAV CAPSIDS FOR TARGETING HUMAN TRANSFERRIN RECEPTORFiled as BIOGEN MA INC.2025-03-27JOSEPH WALTER ARNDT | pending |
| MONOVALENT ANTIBODIES AND USES THEREOFFiled as Biogen MA Inc.2025-03-07R. Blake Pepinsky | pending |
| 2'-OH DEPROTECTION PROCESS OF RIBONUCLEIC ACIDFiled as BIOGEN MA INC.2025-02-28Xuan Zhou | pending |
| METHODS FOR TREATING ALZHEIMER'S DISEASE WITH O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORFiled as BIOGEN MA INC.2025-02-28FLAVIA CRISTINA NERY O'DONNELL | pending |
| PHARMACEUTICAL COMPOSITIONS AND DOSAGE REGIMENS FOR CLINICAL USE OF ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIESA61K 9/0019, C07K 16/2851, A61P 37/00, A61P 37/02, A61P 37/06, A61P 17/00, A61P 29/00, A61K 47/183, A61K 47/26, A61K2039/505, A61K2039/545Filed as Biogen MA Inc.2025-02-21Mark R.H. Krebs | pending |
| METHODS OF TREATING MULTIPLE SCLEROSISA61K 31/225, A61K 47/542, A61K 47/545, A61P 37/00, A61P 21/00, A61P 37/02, A61P 25/28, A61P 25/02, Y02A 50/30, A61P 25/00, A61K 9/0053, A61K 9/20, A61K 9/28, A61K 9/48, A61K 9/4808, A61K 9/4825, A61K 9/485, A61K 9/4858, A61K 9/4866, A61K 49/0004, G01N 33/492, G09B 19/00Filed as Biogen MA Inc.2025-02-07Mark Novas | pending |
| ANTI-BETA AMYLOID/ANTI-TRANSFERRIN RECEPTOR BISPECIFIC ANTIBODIES AND USES THEREOFFiled as Biogen MA Inc.2025-02-06Joseph Walter Arndt | pending |
| METHODS FOR TREATING SPINAL MUSCULAR ATROPHYFiled as BIOGEN MA INC.2025-01-30JAMES HARVEY | pending |
| COMPOUNDS FOR TREATING HUNTINGTON'S DISEASEC07D 495/04, C07D 519/00, A61P 25/28, A61K 31/437, A61K 31/4545, A61K 31/496, A61K 31/4985, A61K 31/519, C07D 413/04, C07D 491/04Filed as BIOGEN MA INC.2025-01-28Magnus Pfaffenbach | pending |
| ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOFC07K 16/2851, A61P 17/06, A61P 21/00, A61P 37/02, A61P 43/00, A61P 37/06, A61P 19/02, Y02A 50/30, A61P 3/10, A61P 13/12, A61P 29/00, A61P 1/04, A61K 39/395, A61K2039/505, C07K2317/24, C07K2317/33, C07K2317/51, C07K2317/515, C07K2317/54, C07K2317/55, C07K2317/565, C07K2317/567, C07K2317/622, C07K2317/626, C07K2317/73, C07K2317/732, C07K2317/734, C07K2317/76, C07K2317/92Filed as Biogen MA Inc.2025-01-27Justin A. Caravella | pending |
| COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHYA61K 48/005, A61P 21/00, C07K 14/47, C12N 15/113, C12N 15/86, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/322, C12N2320/31, C12N2750/14143, C12N2310/3521, C12N2310/3525Filed as Biogen MA Inc.2025-01-24Anindya Kumar Sen | pending |
| EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOFC07D 491/107, A61K 31/397, A61K 31/4155, A61K 31/443, A61K 31/4433, A61K 31/4525, A61K 31/454, A61K 31/4545, A61K 31/506, A61K 31/5377, C07D 205/12, C07D 401/04, C07D 401/12, C07D 403/12, C07D 405/14, C07D 519/00Filed as BIOGEN MA INC.2025-01-22Felix Gonzalez Lopez de Turiso | pending |
| USE OF PERFUSION SEED CULTURES TO IMPROVE BIOPHARMACEUTICAL FEDBATCH PRODUCTION CAPACITY AND PRODUCT QUALITYC12N 5/0018, C07K 16/00, C07K2317/14, C12N2500/10, C12N2500/22, C12N2500/24, C12N2500/32, C12N2511/00Filed as Biogen MA Inc.2025-01-17William C. Yang | pending |
| TYROSINE KINASE 2 INHIBITORS AND USES THEREOFC07D 401/12, C07F 9/65583, A61P 37/00, A61K 31/444, A61K 31/497, A61K 31/501, A61K 31/506, A61K 31/513, A61K 31/519, A61K 31/53, A61K 31/5365, A61K 31/5377, A61K 31/5383, A61K 31/5386, A61K 31/675, C07B 59/002, C07B2200/05, C07D 213/75, C07D 401/14, C07D 405/14, C07D 413/14, C07D 417/14, C07D 471/04, C07D 487/04, C07D 491/04, C07D 491/048, C07D 491/052, C07D 491/056, C07D 491/08, C07D 491/107, C07D 493/18, C07D 498/04, C07D 498/08, C07D 498/18, C07D 498/20, C07D 513/04, C07D 519/00, C07F 9/5325Filed as BIOGEN MA INC.2025-01-14Jeffrey Vessels | pending |
| ALLYLOXYCARBONYL REAGENTS, OLIGONUCLEOTIDES, AND PREPARATION THEREOFFiled as Biogen MA Inc.2025-01-10Thomas Charles Pickel II | pending |
| TYROSINE KINASE 2 INHIBITORS AND USES THEREOFC07D 471/04, A61P 19/02, A61P 29/00, A61K 31/506Filed as BIOGEN MA INC.2024-12-20Jeffrey Vessels | pending |
| TYK2 INHIBITORSA61K 31/53, C07D 519/00, A61P 29/00, A61K 31/4995, A61K 31/5025, A61K 31/519Filed as BIOGEN MA INC.2024-12-20Tamara Halkina Levin | pending |
| Methods for Treating Alzheimer's DiseaseFiled as Biogen International Neuroscience GmbH2024-12-04Brendon Phillip Boot | pending |
| COMPOSITIONS AND METHODS FOR ADENO-ASSOCIATED VIRUS PRODUCTIONFiled as Biogen MA Inc.2024-11-22Narendra Maheshri | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on BIIB
Company overviewEverything on BIIB in one place, with the price.SEC filingsWhat BIIB's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat BIIB's own officers and directors buy and sell.Who owns itEvery manager reporting a position in BIIB.Funds holding itWhich funds and ETFs hold BIIB, and how big a bet.LobbyingWhat BIIB spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on BIIB's account, and who they worked for.Federal contractsWhat federal agencies pay BIIB.